File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function

TitleInhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function
Authors
KeywordsTumor immunity
B7-H3
Checkpoint inhibition
Immunotherapy
Issue Date2017
Citation
Cell Research, 2017, v. 27, n. 8, p. 1034-1045 How to Cite?
AbstractThe interaction between tumor and the immune system is still poorly understood. Significant clinical responses have been achieved in cancer patients treated with antibodies against the CTLA4 and PD-1/PD-L1 checkpoints; however, only a small portion of patients responded to the therapies, indicating a need to explore additional co-inhibitory molecules for cancer treatment. B7-H3, a member of the B7 superfamily, was previously shown by us to inhibit T-cell activation and autoimmunity. In this study, we have analyzed the function of B7-H3 in tumor immunity. Expression of B7-H3 was found in multiple tumor lines, tumor-infiltrating dendritic cells, and macrophages. B7-H3-deficient mice or mice treated with an antagonistic antibody to B7-H3 showed reduced growth of multiple tumors, which depended on NK and CD8+ T cells. With a putative receptor expressed by cytotoxic lymphocytes, B7-H3 inhibited their activation, and its deficiency resulted in increased cytotoxic lymphocyte function in tumor-bearing mice. Combining blockades of B7-H3 and PD-1 resulted in further enhanced therapeutic control of late-stage tumors. Taken together, our results indicate that the B7-H3 checkpoint may serve as a novel target for immunotherapy against cancer.
Persistent Identifierhttp://hdl.handle.net/10722/293033
ISSN
2023 Impact Factor: 28.1
2023 SCImago Journal Rankings: 9.506
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLee, Young Hee-
dc.contributor.authorMartin-Orozco, Natalia-
dc.contributor.authorZheng, Peilin-
dc.contributor.authorLi, Jing-
dc.contributor.authorZhang, Peng-
dc.contributor.authorTan, Haidong-
dc.contributor.authorPark, Hyun Jung-
dc.contributor.authorJeong, Mira-
dc.contributor.authorChang, Seon Hee-
dc.contributor.authorKim, Byung Seok-
dc.contributor.authorXiong, Wei-
dc.contributor.authorZang, Wenjuan-
dc.contributor.authorGuo, Li-
dc.contributor.authorLiu, Yang-
dc.contributor.authorDong, Zhong Jun-
dc.contributor.authorOverwijk, Willem W.-
dc.contributor.authorHwu, Patrick-
dc.contributor.authorYi, Qing-
dc.contributor.authorKwak, Larry-
dc.contributor.authorYang, Zhiying-
dc.contributor.authorMak, Tak W.-
dc.contributor.authorLi, Wei-
dc.contributor.authorRadvanyi, Laszlo G.-
dc.contributor.authorNi, Ling-
dc.contributor.authorLiu, Dongfang-
dc.contributor.authorDong, Chen-
dc.date.accessioned2020-11-17T14:57:44Z-
dc.date.available2020-11-17T14:57:44Z-
dc.date.issued2017-
dc.identifier.citationCell Research, 2017, v. 27, n. 8, p. 1034-1045-
dc.identifier.issn1001-0602-
dc.identifier.urihttp://hdl.handle.net/10722/293033-
dc.description.abstractThe interaction between tumor and the immune system is still poorly understood. Significant clinical responses have been achieved in cancer patients treated with antibodies against the CTLA4 and PD-1/PD-L1 checkpoints; however, only a small portion of patients responded to the therapies, indicating a need to explore additional co-inhibitory molecules for cancer treatment. B7-H3, a member of the B7 superfamily, was previously shown by us to inhibit T-cell activation and autoimmunity. In this study, we have analyzed the function of B7-H3 in tumor immunity. Expression of B7-H3 was found in multiple tumor lines, tumor-infiltrating dendritic cells, and macrophages. B7-H3-deficient mice or mice treated with an antagonistic antibody to B7-H3 showed reduced growth of multiple tumors, which depended on NK and CD8+ T cells. With a putative receptor expressed by cytotoxic lymphocytes, B7-H3 inhibited their activation, and its deficiency resulted in increased cytotoxic lymphocyte function in tumor-bearing mice. Combining blockades of B7-H3 and PD-1 resulted in further enhanced therapeutic control of late-stage tumors. Taken together, our results indicate that the B7-H3 checkpoint may serve as a novel target for immunotherapy against cancer.-
dc.languageeng-
dc.relation.ispartofCell Research-
dc.subjectTumor immunity-
dc.subjectB7-H3-
dc.subjectCheckpoint inhibition-
dc.subjectImmunotherapy-
dc.titleInhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function-
dc.typeArticle-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1038/cr.2017.90-
dc.identifier.pmid28685773-
dc.identifier.pmcidPMC5539354-
dc.identifier.scopuseid_2-s2.0-85026672802-
dc.identifier.volume27-
dc.identifier.issue8-
dc.identifier.spage1034-
dc.identifier.epage1045-
dc.identifier.eissn1748-7838-
dc.identifier.isiWOS:000406639800009-
dc.identifier.issnl1001-0602-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats